review Open AccessTop 1% cited

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Nature reviews. Cancer · 2016 · Vol. 16(5) · pp. 275–287

Suzanne L. Topalian✉(Johns Hopkins University)Janis M. Taube(Sidney Kimmel Comprehensive Cancer Center)Robert A. Anders(Bloomberg (United States))Drew M. Pardoll(Johns Hopkins University)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Immune Cell Function and InteractionImmune checkpointBlockadeImmune systemCancerMedicineBiomarkerMelanomaMechanism (biology)Cytotoxic T cellImmunotherapy

MeSH terms

HumansNeoplasmsBiomarkers, TumorCell Cycle CheckpointsB7-H1 AntigenCTLA-4 Antigen

Citations

2,679

FWCI

129.55

field-weighted impact

References

128

Percentile

100%

vs. same field & year

Citations per year

Cited by

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Advanced Science · 2022 · 620 citations

Breast Cancer Immunotherapy: Facts and Hopes

Clinical Cancer Research · 2017 · 917 citations

CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review

Journal of Cellular Physiology · 2018 · 1,708 citations

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Clinical Cancer Research · 2016 · 984 citations

Frontiers in Pharmacology · 2017 · 465 citations

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Frontiers in Pharmacology · 2021 · 406 citations

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

Cancer Cell · 2017 · 1,372 citations

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Frontiers in Pharmacology · 2017 · 1,726 citations

References

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Nature Medicine · 1999 · 2,463 citations

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

Human Pathology · 2015 · 336 citations

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

New England Journal of Medicine · 2015 · 9,308 citations

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Nature Medicine · 2003 · 2,279 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of Clinical Oncology · 2010 · 2,913 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Nature Medicine · 2002 · 4,970 citations

The immune contexture in human tumours: impact on clinical outcome

Nature reviews. Cancer · 2012 · 4,857 citations

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Science · 2015 · 7,864 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.